Kamada Ltd provides plasma-derived protein therapeutics, operating in two segments: Proprietary Products and Distribution, offering a range of products such as KAMRAB/KEDRAB for rabies disease prophylaxis and CYTOGAM for cytomegalovirus disease prophylaxis among others. The company distributes various products in the USA and internationally through strategic partners and distributors. Kamada also has strategic partnerships with other pharmaceutical companies such as Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma.